Mahendra S. Rao
Founder at Q Therapeutics, Inc.
Mahendra S. Rao active positions
Companies | Position | Start | End |
---|---|---|---|
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Chairman | 2009-10-25 | - |
Q Therapeutics, Inc.
Q Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT. | Director/Board Member | - | - |
Founder | 2002-02-28 | - | |
Corporate Officer/Principal | 2002-02-28 | - | |
panCELLa, Inc.
panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Chairman | - | - |
Implant Therapeutics
Implant Therapeutics Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., Implant Therapeutics is a Canadian biotechnology company that develops therapeutic products in the immunology, mesenchymal stem cell, and pancreatic islet space. The company partners with other companies to develop novel products in other areas of regenerative medicine. Under the guidance of Dr. Mahendra Rao, Implant Therapeutics engineers hypoimmunogenic and safe-harbor technologies in ipsc-msc and islets. These cells are an ideal choice for bone, cartilage, and tendon replacement strategies, combining the advantages of allogeneic and autologous cells, as well as allowing them to be used as ex-vivo gene therapy vehicles. The CEO of the company is Mahendra S. Rao. | Chief Executive Officer | 2021-11-30 | - |
Career history of Mahendra S. Rao
Former positions of Mahendra S. Rao
Companies | Position | Start | End |
---|---|---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Director/Board Member | 2011-08-03 | 2011-08-03 |
Corporate Officer/Principal | 2011-08-03 | 2013-12-31 | |
THERMOGENESIS HOLDINGS, INC. | Director/Board Member | 2007-12-31 | 2011-07-28 |
THERMO FISHER SCIENTIFIC | Corporate Officer/Principal | 2010-12-31 | 2010-12-31 |
National Institute on Aging | Corporate Officer/Principal | 2000-12-31 | - |
THERMOGENESIS HOLDINGS, INC. | Director/Board Member | 2014-03-31 | - |
Independent Dir/Board Member | 2014-03-31 | - | |
░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░ ░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░ ░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░ ░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Mahendra S. Rao
California Institute of Technology | Doctorate Degree |
University of Mumbai | Undergraduate Degree |
Statistics
International
United States | 12 |
India | 3 |
Canada | 3 |
Operational
Corporate Officer/Principal | 9 |
Director/Board Member | 4 |
Founder | 2 |
Sectoral
Commercial Services | 5 |
Consumer Services | 5 |
Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
THERMOGENESIS HOLDINGS, INC. | Health Technology |
THERMO FISHER SCIENTIFIC | Health Technology |
Private companies | 9 |
---|---|
Invitrogen Corp.
Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Invitrogen develops, manufactures and markets research tools in kit form and provides other research products and services to corporate, academic and government entities. These research kits simplify and improve gene cloning, gene expression and gene analysis techniques. | Electronic Technology |
Q Therapeutic Products, Inc.
Q Therapeutic Products, Inc. Miscellaneous Commercial ServicesCommercial Services Q Therapeutic Products, Inc. develops novel products to treat debilitating and fatal diseases. The company was founded by Dennis B. Farrar and Mahendra S. Rao in 2004 and is headquartered in Salt Lake, UT. | Commercial Services |
Q Therapeutics, Inc.
Q Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT. | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Government |
National Centre for Biological Sciences
National Centre for Biological Sciences Miscellaneous Commercial ServicesCommercial Services The National Centre for Biological Sciences (NCBS) is a research institute located in Bangalore, IN. The Tata Institute for Genetics and Society (TIGS) is a non-profit research institute that aspires to develop solutions to challenges in human health and agriculture using applications of cutting-edge science and technology in genetics and genomics. The NCBS conducts research on various topics such as the assembly of mixed and branched heterotypic ubiquitin chains, evolution, and dopamine-neuropeptide axis maintenance in Drosophila. The institute has also been involved in tracking COVID and dengue through sewage surveillance. The institute is part of the Tata Institute of Fundamental Research and is dedicated to the study of stem cell and regenerative biology. The center for cellular and molecular platforms (C-CAMP) is an initiative of the Department of Biotechnology, Ministry of Science and Technology, with a mandate to be an enabler of cutting-edge life science research and innovation. | Commercial Services |
National Institute on Aging | Government |
panCELLa, Inc.
panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Commercial Services |
Implant Therapeutics
Implant Therapeutics Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., Implant Therapeutics is a Canadian biotechnology company that develops therapeutic products in the immunology, mesenchymal stem cell, and pancreatic islet space. The company partners with other companies to develop novel products in other areas of regenerative medicine. Under the guidance of Dr. Mahendra Rao, Implant Therapeutics engineers hypoimmunogenic and safe-harbor technologies in ipsc-msc and islets. These cells are an ideal choice for bone, cartilage, and tendon replacement strategies, combining the advantages of allogeneic and autologous cells, as well as allowing them to be used as ex-vivo gene therapy vehicles. The CEO of the company is Mahendra S. Rao. | Commercial Services |
- Stock Market
- Insiders
- Mahendra S. Rao
- Experience